These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 2656617)
21. L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa. Valiant ME; Gilfillan EC; Gadebusch HH; Pelak BA J Antibiot (Tokyo); 1989 May; 42(5):807-14. PubMed ID: 2498278 [TBL] [Abstract][Full Text] [Related]
22. The post-antibiotic effect of antimicrobial combinations in a neutropenic murine thigh infection model. Gudmundsson S; Einarsson S; Erlendsdottir H; Moffat J; Bayer W; Craig WA J Antimicrob Chemother; 1993 May; 31 Suppl D():177-91. PubMed ID: 8335520 [TBL] [Abstract][Full Text] [Related]
23. [Correlation between pulmonary pharmacokinetics and pharmacodynamics support the hypothesis of the usefulness of ceftazidime at a single 1g daily dose in the treatment of bacterial exacerbation of chronic obstructive bronchopneumonia with moderate functional damage]. Cazzola M; Noschese P; Vinciguerra A; Di Perna F; Califano C; Berra A Minerva Med; 1998; 89(1-2):15-22. PubMed ID: 9561021 [TBL] [Abstract][Full Text] [Related]
24. [Experiences with ceftazidime in the therapy of neonatal infections]. de Louvois J Infection; 1987; 15 Suppl 4():S209-13. PubMed ID: 3312037 [TBL] [Abstract][Full Text] [Related]
25. Ceftazidime in patients with Pseudomonas infections. Eron LJ; Park CH; Hixon DL; Goldenberg RI; Poretz DM J Antimicrob Chemother; 1983 Jul; 12 Suppl A():161-9. PubMed ID: 6225762 [TBL] [Abstract][Full Text] [Related]
26. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. Jones RN; Barry AL; Thornsberry C; Gerlach EH; Fuchs PC; Gavan TL; Sommers HM J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985 [TBL] [Abstract][Full Text] [Related]
27. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae. Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163 [TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics of ceftazidime in febrile neutropenic patients. Nyhlén A; Ljungberg B; Nilsson-Ehle I Scand J Infect Dis; 2001; 33(3):222-6. PubMed ID: 11303815 [TBL] [Abstract][Full Text] [Related]
29. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [TBL] [Abstract][Full Text] [Related]
30. Antibacterial and pharmacokinetic properties of M14659, a new injectable semisynthetic cephalosporin. Mochizuki H; Oikawa Y; Yamada H; Kusakabe S; Shiihara T; Murakami K; Kato K; Ishiguro J; Kosuzume H J Antibiot (Tokyo); 1988 Mar; 41(3):377-91. PubMed ID: 3130365 [TBL] [Abstract][Full Text] [Related]
31. Relapsing infection due to Enterobacter species: lessons of heterogeneity. Medeiros AA Clin Infect Dis; 1997 Aug; 25(2):341-2. PubMed ID: 9332546 [No Abstract] [Full Text] [Related]
32. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa. Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848 [TBL] [Abstract][Full Text] [Related]
33. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin. Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic efficacy of cefpiramide-ciprofloxacin combination in experimental Pseudomonas infections in neutropenic mice. Fu KP; Hetzel N; Gregory FJ; Hung PP J Antimicrob Chemother; 1987 Oct; 20(4):541-6. PubMed ID: 3680089 [TBL] [Abstract][Full Text] [Related]
35. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. Seifert H; Körber-Irrgang B; Kresken M; Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime. Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406 [TBL] [Abstract][Full Text] [Related]
37. Amikacin in obstetric, gynecologic, and neonatal infections: laboratory and clinical studies. Mazzei T; Paradiso M; Nicoletti I; Periti P J Infect Dis; 1976 Nov; 134 SUPPL():S374-9. PubMed ID: 993629 [TBL] [Abstract][Full Text] [Related]
38. Activity of Ceftolozane-Tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates Collected from Respiratory Tract Specimens of Hospitalized Patients in the United States during 2013 to 2015. Castanheira M; Duncan LR; Mendes RE; Sader HS; Shortridge D Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263073 [TBL] [Abstract][Full Text] [Related]
39. [HR 810 (cefpirome). Experimental evaluation of the in vitro and in vivo antibiotic activity of a new amino-2-thiazole methoxy- imino cephalosporin]. Chantot JF; Bryskier A Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):482-6. PubMed ID: 3937124 [TBL] [Abstract][Full Text] [Related]